Navigation Links
Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
Date:3/2/2009

VANCOUVER, March 2 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced it has obtained a new Senior Secured Term Loan and Revolving Credit Facility. Wells Fargo Foothill, LLC is the sole arranger, administrative agent and lender for both the Term Loan and Revolving Credit Facility.

The financing includes a delayed draw secured term loan facility of up to $10 million, and a secured revolving credit facility with a borrowing base derived from the value of certain of the Company's finished goods inventory and accounts receivable, providing up to an additional $22.5 million in available credit, subject to certain terms and conditions. Any borrowings outstanding under the term loan and revolving credit facility bear interest ranging from LIBOR + 3.25% to LIBOR +3.75%, with a minimum Base LIBOR Rate of 2.25%. The term loan and the revolving credit facility include certain covenants and restrictions with respect to our operations, require us to maintain certain levels of Adjusted EBITDA and interest coverage ratios, among other terms and conditions, and are secured by the assets of the Company and its Canadian and US subsidiaries. The purpose of the financings is to provide additional liquidity and capital resources for working capital and general corporate purposes.

"We believe this financing will provide enhanced liquidity in the near term and provide us more flexibility and time for Angiotech to explore other longer-term options for our overall capital structure and working capital needs," said Dr. William Hunter, President and CEO of Angiotech. "We would like to thank Wells Fargo Foothill for their confidence in our business plan and providing us with capital in a difficult capital markets environment."

    Forward Looking Statements
    --------------------------

Statement
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Angiotech Pharmaceuticals announces time change of conference call and webcast
2. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
3. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
4. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
5. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
6. Angiotech wins before the UK House of Lords
7. Angiotech to Establish Separate Operating and Royalty Businesses
8. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
9. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
10. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
11. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 2La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 2CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 3
Breaking Biology News(10 mins):Berkeley Lab researchers participate in Homeland Security study of subway airflow 2Potential new heart attack biomarker uncovered 2Successful stem cell therapy for treatment of eye disease 2Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 1Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 2Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 3Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 4Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 5Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 6Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 7Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 8Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 9Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 10Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 11Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 12Reportlinker Adds Medical Devices 26amp 3B Equipment in India 282009 29 5714 13Hutchinson Center to Build First U S Cancer Clinic and Training Facility in Africa Thanks in Part to a Grant From USAID 5711 1Hutchinson Center to Build First U S Cancer Clinic and Training Facility in Africa Thanks in Part to a Grant From USAID 5711 2Hutchinson Center to Build First U S Cancer Clinic and Training Facility in Africa Thanks in Part to a Grant From USAID 5711 3Hutchinson Center to Build First U S Cancer Clinic and Training Facility in Africa Thanks in Part to a Grant From USAID 5711 4Hutchinson Center to Build First U S Cancer Clinic and Training Facility in Africa Thanks in Part to a Grant From USAID 5711 5Hutchinson Center to Build First U S Cancer Clinic and Training Facility in Africa Thanks in Part to a Grant From USAID 5711 6MolSofts New Technology Brings Online Publications to Life in Fully Interactive 3D 5708 1MolSofts New Technology Brings Online Publications to Life in Fully Interactive 3D 5708 2